Investigational Medication CURE Studies
|Goal||The combination of HXTC therapy and multiple doses of VOR will result in a depletion of persistent, latent, replication competent HIV infection.|
|Who is eligible to participate||HIV-infected men and women, ≥18 and < 65 years of age, with durable viral suppression as measured on standard HIV RNA assays for ≥24 months. Eligible participants must be on stable combination ART (cART) and have a CD4 count ≥350 cells/mm3.|
|Medication||Vorinostat and Expanded Specific T-Cell Therapy|
|Duration||Up to 48 months|
|Compensation||Total: $3700. Travel & parking compensation are offered as well.|
|Goal||Characterize the safety and tolerability of MGD014 administered intravenously (IV) to HIV-infected participants maintained on suppressive ART.|
|Who is eligible to participate||HIV-1-infected adults (18 to 65 years old) on ART with plasma HIV RNA < 50 copies/mL for 24 months prior to enrollment.Eligible participants must be on stable combination ART (cART) and have a CD4 count ≥ 350 cells/mm3.|
|Medication||MGD014 administered via a single infusion in Part 1 or a weekly infusion, for 6 weeks, in Part 2|
|Duration||10 weeks (Part 1) or 20 weeks (Part 2)|
|Compensation||Part 1: Step 1 – $100, Step 2 – up to $750, Step 3 – $150, Total – up to $1000.
Part 2: Step 1 – $300, Step 2 – $1350, Step 3 – $400, Total – $2050.
Travel & parking compensation are offered as well.
|Goal||The purpose of this study is to test a drug that has not been tested in humans before now. This experimental drug is called SAR441236.|
|Who is eligible to participate||HIV infected men and women who have never received ART or who have taken ART for > 12 months|
|Medication||SAR441236 via 1- 4 IV infusions|
|Compensation||Visits – $50, Infusion visits with PK – $250. Arm A, groups 1-3, Total – $800. Arm A, group 4, Total – $1,950. Arm B, all groups, Total – $850. Travel & parking compensation are offered as well.|
For information about additional studies that are coming soon please visit here.